A Randomized, Single-blind, Placebo Controlled, Dose-ranging Phase II Trial in ≥ 55 Year Old Adults to Evaluate the Safety and Immunogenicity of the Recombinant MVA-BN-RSV Vaccine

Trial Profile

A Randomized, Single-blind, Placebo Controlled, Dose-ranging Phase II Trial in ≥ 55 Year Old Adults to Evaluate the Safety and Immunogenicity of the Recombinant MVA-BN-RSV Vaccine

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Sep 2017

At a glance

  • Drugs MVA-BN RSV (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Pharmacodynamics
  • Sponsors Bavarian Nordic
  • Most Recent Events

    • 21 Sep 2017 According to Bavarian Nordic media release, the company announced initial 6 month follow-up data of this trial.
    • 20 Jul 2017 Planned End Date changed from 1 Jul 2017 to 1 Aug 2018.
    • 20 Jul 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Aug 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top